COLINZPharmaceuticals
Colinz Laboratories Ltd — Profit & Loss Statement
₹44.50
+0.00%
Colinz Laboratories Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -51518.51 | 10861.96 | — |
| Tax Rate For Calcs | 0.20 | 0.25 | 0.24 | 0.29 | — |
| Normalized EBITDA | 0.79 Cr | 0.82 Cr | 0.80 Cr | 0.75 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | -0.02 Cr | 37000.00 | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | -0.02 Cr | 37000.00 | — |
| Net Income From Continuing Operation Net Minority Interest | 0.50 Cr | 0.49 Cr | 0.45 Cr | 0.34 Cr | — |
| Reconciled Depreciation | 0.13 Cr | 0.13 Cr | 0.13 Cr | 0.20 Cr | — |
| Reconciled Cost Of Revenue | 2.09 Cr | 2.31 Cr | 2.52 Cr | 2.61 Cr | — |
| EBITDA | 0.79 Cr | 0.82 Cr | 0.78 Cr | 0.76 Cr | — |
| EBIT | 0.66 Cr | 0.69 Cr | 0.65 Cr | 0.56 Cr | — |
| Net Interest Income | -0.04 Cr | -0.04 Cr | 0.11 Cr | 0.09 Cr | — |
| Interest Expense | 0.04 Cr | 0.04 Cr | 0.05 Cr | 0.08 Cr | — |
| Normalized Income | 0.50 Cr | 0.49 Cr | 0.47 Cr | 0.34 Cr | — |
| Net Income From Continuing And Discontinued Operation | 0.50 Cr | 0.49 Cr | 0.45 Cr | 0.34 Cr | — |
| Total Expenses | 6.16 Cr | 6.62 Cr | 6.65 Cr | 6.59 Cr | — |
| Diluted Average Shares | 0.25 Cr | 0.25 Cr | 0.25 Cr | 0.46 Cr | — |
| Basic Average Shares | 0.25 Cr | 0.25 Cr | 0.25 Cr | 0.46 Cr | — |
| Diluted EPS | 1.97 | 1.93 | 1.82 | 0.74 | — |
| Basic EPS | 1.97 | 1.93 | 1.82 | 0.74 | — |
| Diluted NI Availto Com Stockholders | 0.50 Cr | 0.49 Cr | 0.45 Cr | 0.34 Cr | — |
| Net Income Common Stockholders | 0.50 Cr | 0.49 Cr | 0.45 Cr | 0.34 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 0.50 Cr | 0.49 Cr | 0.45 Cr | 0.34 Cr | — |
| Net Income Including Noncontrolling Interests | 0.50 Cr | 0.49 Cr | 0.46 Cr | 0.34 Cr | — |
| Net Income Continuous Operations | 0.50 Cr | 0.49 Cr | 0.46 Cr | 0.34 Cr | — |
| Tax Provision | 0.12 Cr | 0.16 Cr | 0.14 Cr | 0.14 Cr | — |
| Pretax Income | 0.62 Cr | 0.65 Cr | 0.60 Cr | 0.48 Cr | — |
| Other Non Operating Income Expenses | 0.30 Cr | 0.28 Cr | 0.17 Cr | 0.17 Cr | — |
| Special Income Charges | 0.00 | 0.00 | -0.02 Cr | 37000.00 | — |
| Net Non Operating Interest Income Expense | -0.04 Cr | -0.04 Cr | 0.11 Cr | 0.09 Cr | — |
| Interest Expense Non Operating | 0.04 Cr | 0.04 Cr | 0.05 Cr | 0.08 Cr | — |
| Operating Income | 0.36 Cr | 0.41 Cr | 0.50 Cr | 0.39 Cr | — |
| Operating Expense | 4.07 Cr | 4.30 Cr | 4.13 Cr | 3.98 Cr | — |
| Other Operating Expenses | 1.10 Cr | 1.22 Cr | 0.55 Cr | 0.51 Cr | — |
| Depreciation And Amortization In Income Statement | 0.13 Cr | 0.13 Cr | 0.13 Cr | 0.20 Cr | — |
| Depreciation Income Statement | 0.13 Cr | 0.13 Cr | 0.13 Cr | 0.20 Cr | — |
| Gross Profit | 4.44 Cr | 4.72 Cr | 4.64 Cr | 4.36 Cr | — |
| Cost Of Revenue | 2.09 Cr | 2.31 Cr | 2.52 Cr | 2.61 Cr | — |
| Total Revenue | 6.53 Cr | 7.03 Cr | 7.15 Cr | 6.97 Cr | — |
| Operating Revenue | 6.53 Cr | 7.03 Cr | 7.15 Cr | 6.97 Cr | — |
| Interest Income | — | 0.27 Cr | 0.16 Cr | 0.16 Cr | 0.19 Cr |
| Rent Expense Supplemental | — | 0.17 Cr | 0.17 Cr | 0.14 Cr | 0.16 Cr |
| Interest Income Non Operating | — | 0.27 Cr | 0.16 Cr | 0.16 Cr | 0.19 Cr |
| Selling General And Administration | — | 0.24 Cr | 0.24 Cr | 0.21 Cr | 0.19 Cr |
| Selling And Marketing Expense | — | 0.07 Cr | 0.06 Cr | 0.06 Cr | 0.08 Cr |
| General And Administrative Expense | — | 0.18 Cr | 0.18 Cr | 0.15 Cr | 0.11 Cr |
| Rent And Landing Fees | — | 0.17 Cr | 0.17 Cr | 0.14 Cr | 0.16 Cr |
| Other Special Charges | — | — | 0.02 Cr | -37000.00 | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Colinz Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.